ArticleReviews in cardiovascular medicine2026
Plasma Steroids as Biomarkers of Congestion and Predictors of Prognosis in Acute Heart Failure During the Vulnerable Phase.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with heart failure (HF) are at high risk of mortality and readmission during the 90-day "vulnerable phase" post-discharge, often because of persistent congestion. However, tools effective for assessing risk are lacking. Thus, this study aimed to develop a steroid-based congestion score from the plasma steroid profile and determine the associated prognostic value during the vulnerable phase in patients with acute HF. Methods: Plasma levels of 18 steroids were measured by liquid chromatography-tandem mass spectrometry in patients from the Registry Study of Biomarkers in Heart Failure. Patients were divided into a discovery cohort for biomarker screening and model development (n = 691), a cohort for validation of prognostic value (validation cohort 1, n = 267), and a cohort with paired discharge and 90-day plasma samples available for assessment of dynamic changes in biomarkers (validation cohort 2, n = 46). Steroids independently associated with the clinical congestion score (CCS) were identified by correlation analysis and multivariable logistic regression and were used to construct the "steroid-based" congestion score (SCS). The 90-day prognostic value of the SCS was assessed using Cox regression, and the incremental predictive ability of the SCS was quantified using integrated discrimination improvement. Results: The SCS included cortisol, dehydroepiandrosterone sulfate, and pregnenolone. In the discovery cohort, an SCS ≥-0.563 was associated with a 2.02-fold increase in the risk of the 90-day composite endpoint of all-cause death and HF readmission (95% confidence interval, 1.42-2.88). Adding the SCS to clinical, B-type natriuretic peptide, and clinical congestion score model increased the integrated discrimination improvement by 1.2%, 0.8%, and 1.0%, respectively (all Conclusions: The SCS independently predicts adverse outcomes during the vulnerable phase in patients with HF, offering incremental prognostic value beyond traditional indicators and potentially supporting dynamic monitoring for individualized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.